Skip to main content Skip to search Skip to main navigation
News: Europe

Mutual recognition of inspections under the EU-UK Trade Agreement

Questions about the EU-UK Trade and Cooperation Agreement, which will apply from January 1, 2021, were clarified by the European Commission in a 39-page Q&A on the EU-UK Trade and Cooperation Agreement on December 24, 2020. In total, it consists of 133 pairs of questions and answers.

To avoid supply delays and duplicate inspections, the EU and UK also mutually recognize inspections and GMP certificates. Recognition applies to manufacturers located within the territory of the issuing authority. Under certain conditions, a party may extend recognition to manufacturers outside the territory. 

The 1449-page trade and cooperation agreement covers the following areas:  

  • Trade in goods and services 
  • Digital trade 
  • Intellectual property 
  • Public procurement 
  • Aviation and road transport 
  • Energy 
  • Fisheries  
  • Social security coordination 
  • Law enforcement and judicial cooperation in criminal matters 
  • Thematic cooperation and participation in Union programs  

The detailed provisions on pharmaceuticals are found in Annex TBT-2, which comprises 12 articles and three annexes.   


Sources:

EUR-Lex: Trade and Cooperation Agreement between the European Union and the European Atomic Energy Community of the one Part, and the United Kingdom of Great Britain and Northern Ireland, of the other Part

EC: Questions & Answers: EU-UK Trade and Cooperation Agreement 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next